3,301 results match your criteria Antiphospholipid Antibody Syndrome and Pregnancy


The association between chronic liver diseases and preeclampsia.

BMC Pregnancy Childbirth 2022 Jun 20;22(1):500. Epub 2022 Jun 20.

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Background: Preeclampsia is a multisystem disorder characterized by an abnormal vascular response to placentation associated with increased systemic vascular resistance. As liver involvement is one of the main clinical features of preeclampsia, we sought to determine if there is an association between chronic liver diseases and preeclampsia.

Methods: A retrospective matched case-control analysis was conducted in a tertiary medical center. Read More

View Article and Full-Text PDF

Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives.

Vasc Health Risk Manag 2022 10;18:359-373. Epub 2022 May 10.

Therapeutic and Vascular Medicine Department, University Hospital of Saint Etienne, Saint Etienne, France.

During the past decade, emergence of direct oral anticoagulants (DOACs) has drastically improved the prevention of thrombosis. However, several unmet needs prevail in the field of thrombosis prevention, even in the DOACs' era. The use of DOACs is still constrained and the drugs cannot be administered in every clinical scenario, such as an increased anticoagulant-associated bleeding risk, particularly in some specific populations (cancer - notably those with gastrointestinal or genitourinary cancer - and frail patients), the impossibility to be used in certain patients (eg, end-stage kidney failure during hemodialysis, pregnancy and breastfeeding), and their lack of efficacy in certain clinical scenarios (eg, mechanical heart valves, triple-positive antiphospholipid syndrome). Read More

View Article and Full-Text PDF

Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry').

Lupus Sci Med 2022 06;9(1)

Rheumatology, Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York, USA

Objectives: To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since the inception of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Registry.

Methods: We identified persistently aPL-positive patients recorded as 'pregnant' during prospective follow-up, and defined as a composite of: (1) Preterm live delivery (PTLD) at or before 37th week due to pre-eclampsia (PEC), eclampsia, small-for-gestational age (SGA) and/or placental insufficiency (PI); or (2) Otherwise unexplained fetal death after the 10th week of gestation. The primary objective was to describe the characteristics of patients with and without aPL-related composite outcomes based on their first observed pregnancies following registry recruitment. Read More

View Article and Full-Text PDF

Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study.

Arthritis Res Ther 2022 Jun 11;24(1):140. Epub 2022 Jun 11.

Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by persistent antiphospholipid antibodies (aPLs) positivity with a wide manifestation spectrum. A risk stratification is needed for management guidance and prognosis assessment. We aimed to identify phenotypes among aPL-positive patients and assess the prognosis of each phenotype. Read More

View Article and Full-Text PDF

Epigenetics-mediated pathological alternations and their potential in antiphospholipid syndrome diagnosis and therapy.

Autoimmun Rev 2022 Jun 9;21(8):103130. Epub 2022 Jun 9.

Department of Laboratory Medicine, Peking University Third Hospital, Beijing, 100191, China; Core Unit of National Clinical Research Center for Laboratory Medicine, Peking University Third Hospital, Beijing 100191, China. Electronic address:

APS (antiphospholipid syndrome) is a systematic autoimmune disease accompanied with venous or arterial thrombosis and poor pregnant manifestations, partly attributing to the successive elevated aPL (antiphospholipid antibodies) and provoked prothrombotic and proinflammatory molecules production. Nowadays, most researches focus on the laboratory detection and clinic features of APS, but its precise etiology remains to be deeply explored. As we all know, the dysfunction of ECs (endothelial cells), monocytes, platelets, trophoblasts and neutrophils are key contributors to APS progression. Read More

View Article and Full-Text PDF

Antiphospholipid Antibodies Increase the Risk of Fetal Growth Restriction: A Systematic Meta-Analysis.

Int J Clin Pract 2022 31;2022:4308470. Epub 2022 Jan 31.

Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, China.

Objective: Antiphospholipid syndrome (APS) is a chronic autoimmune disease with a high prevalence in females. Published data have identified pregnant women with APS may suffer from recurrent miscarriage, fetal death. However, the association between antiphospholipid antibody (aPL) and fetal growth restriction (FGR) remains controversial. Read More

View Article and Full-Text PDF

Improved pregnancy outcomes in systemic lupus erythematosus: A retrospective study of pregnancies from a single centre in Denmark from 2010-2020 compared with the period 1990-2010.

Lupus 2022 Jun 8:9612033221107538. Epub 2022 Jun 8.

Department of Rheumatology, 11297Aarhus University Hospital, Aarhus, Denmark.

Objectives: Over the past decades new international guidelines recommend that pregnant Systemic lupus erythematosus (SLE) patients are monitored closely in a multi-professional team throughout pregnancy. The importance of low disease activity before pregnancy and continued treatment during pregnancy has been established. However, there is still a high risk of adverse pregnancy outcome (APO). Read More

View Article and Full-Text PDF

Treatment of Refractory/High-Risk Pregnancies With Antiphospholipid Syndrome: A Systematic Review of the Literature.

Front Pharmacol 2022 19;13:849692. Epub 2022 May 19.

General Internal Medicine and Thrombotic and Hemorrhagic Unit, University of Padua, Padua, Italy.

Different treatment protocols have been employed to manage heparin/low-dose aspirin refractory or high-risk pregnancies in antiphospholipid antibody syndrome (APS) pregnancies. A systematic review of the literature on additional treatments used in refractory and/or high-risk APS pregnancies was conducted. Records from February 2006 to October 2021 were retrieved from PubMed, Web of Science, Cochrane, and the www. Read More

View Article and Full-Text PDF

[Clinical Confusion Concerning Increased D-Dimer Value during Pregnancy].

Sichuan Da Xue Xue Bao Yi Xue Ban 2022 May;53(3):543-548

Department of Obstetrics, West China Second University Hospital, Chengdu 610041, China.

Plasma D-dimer, a special cross-linked fibrin derivative, is produced when fibrin is degraded by plasminase. During pregnancy, D-dimer increases along with the increase of gestational age, and the reference value of plasma D-dimer (≤0.5 mg/L) traditionally used for the screening of venous thrombosis in the normal population is not applicable to the pregnant population. Read More

View Article and Full-Text PDF

Anticardiolipin IgA as a Potential Risk Factor for Pregnancy Morbidity in Patients with Antiphospholipid Syndrome.

Lab Med 2022 May 29. Epub 2022 May 29.

Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China.

Background: Antiphospholipid syndrome (APS) is an autoimmune disorder that is characterized by venous or arterial thrombosis and/or obstetric morbidity in the constant presence of persistent antiphospholipid antibodies (aPLs). In patients with APS, the relationship between production of immunoglobulin (Ig)A antiphospholipid antibodies and adverse events in pregnancy is still unclear. As a result of massive trials, the clinical efficiency of IgA-aPLs is used to evaluate pregnancy outcomes in patients with APS. Read More

View Article and Full-Text PDF

Treatment advances in antiphospholipid syndrome: 2022 update.

Curr Opin Pharmacol 2022 May 27;65:102212. Epub 2022 May 27.

Barbara Volcker Center for Women and Rheumatic Diseases, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA. Electronic address:

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, pregnancy morbidity, or non-thrombotic manifestations in patients with persistently positive antiphospholipid antibodies (aPL). Conventional treatment strategies of antiphospholipid syndrome focuses on antithrombotic agents, however they are usually not effective for microvascular and non-thrombotic manifestations of aPL. In parallel to our increased understanding of the mechanisms of aPL-mediated clinical events, immunosuppression has been increasingly used in aPL-positive patients. Read More

View Article and Full-Text PDF

Effects of Comprehensive Nursing Based on Orem's Self-Care Theory on Symptom Improvement and Pregnancy Outcome in Patients with Antiphospholipid Syndrome: A Retrospective Cohort Study.

Comput Math Methods Med 2022 19;2022:4133812. Epub 2022 May 19.

Obstetrics Department of Beijing Chaoyang Hospital, Capital Medical University 100020, China.

Objective: A retrospective cohort study was conducted to explore the effects of comprehensive nursing based on Orem's self-care theory on symptom improvement and pregnancy outcomes in patients with antiphospholipid syndrome (APS).

Methods: Sixty patients with antiphospholipid antibody syndrome treated in our hospital from February 2019 to April 2021 were enrolled. The control group received comprehensive nursing, while the study group received comprehensive nursing based on Orem's self-care theory. Read More

View Article and Full-Text PDF

Thrombocytopenia in primary antiphospholipid syndrome: Association with prognosis and clinical implications.

Rheumatology (Oxford) 2022 May 10. Epub 2022 May 10.

Department of Rheumatology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China.

Objectives: Thrombocytopenia, a frequent clinical manifestation in patients with antiphospholipid syndrome (APS), could be an independent predictor of recurrent thrombotic, obstetrical and severe extra-criteria events.

Methods: This single-center prospective study enrolled 218 consecutive patients diagnosed with primary APS between 2010 to 2021. Thrombocytopenia was defined as a platelet count <100 × 109/L. Read More

View Article and Full-Text PDF

Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome.

Front Pharmacol 2022 21;13:824775. Epub 2022 Apr 21.

Clinical Immunology, Angioedema and Allergy Unit, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.

Primary obstetric antiphospholipid syndrome (OAPS) is defined by specific morbidities and/or losses of pregnancy in the presence of persistent antiphospholipid antibodies (aPL). This variant of APS is usually treated during pregnancy and the post-partum period. Data on occurrence of thrombotic event during long term follow-up of OAPS patients is limited. Read More

View Article and Full-Text PDF

Restriction of the Global IgM Repertoire in Antiphospholipid Syndrome.

Front Immunol 2022 13;13:865232. Epub 2022 Apr 13.

Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.

The typical anti-phospholipid antibodies (APLA) in the anti-phospholipid syndrome (APS) are reactive with the phospholipid-binding protein β2GPI as well as a growing list of other protein targets. The relation of APLA to natural antibodies and the fuzzy set of autoantigens involved provoked us to study the changes in the IgM repertoire in APS. To this end, peptides selected by serum IgM from a 7-residue linear peptide phage display library (PDL) were deep sequenced. Read More

View Article and Full-Text PDF

Diagnosis and management of thrombocytopenia in pregnancy.

Authors:
Young Hoon Park

Blood Res 2022 Apr;57(S1):79-85

Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea.

Thrombocytopenia, defined as platelet count <150×10/L, is frequently observed by physicians during pregnancy, with an incidence of approximately 10% of all pregnancies. Most of the cases of thrombocytopenia in pregnancy are due to gestational thrombocytopenia, which does not confer an increased risk of maternal bleeding. However, because other causes can be associated with life-threatening events, such as severe bleeding, that can affect to maternal and fetal outcomes, differentiating other cause of thrombocytopenia, which includes preeclampsia, HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome, acute fatty liver of pregnancy, immune thrombocytopenia, hereditary thrombocytopenia, antiphospholipid syndrome, thrombotic thrombocytopenic purpura, and atypical hemolytic uremic syndrome, is important. Read More

View Article and Full-Text PDF

PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome.

Front Immunol 2022 11;13:842923. Epub 2022 Apr 11.

Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom.

Antiphospholipid syndrome (APS) is an autoimmune disorder in which autoantibodies cause clinical effects of vascular thrombosis and pregnancy morbidity. The only evidence-based treatments are anticoagulant medications such as warfarin and heparin. These medications have a number of disadvantages, notably risk of haemorrhage. Read More

View Article and Full-Text PDF

Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center.

Arthritis Res Ther 2022 04 27;24(1):91. Epub 2022 Apr 27.

Department of Autoimmune Diseases, Hospital Clinic, Universitat de Barcelona, Villarroel, 08036, Barcelona, Catalonia, Spain.

Background: Pregnancy in systemic sclerosis (SSc) patients is no more an infrequent event as it used to be, but literature data on pregnancy outcomes in women with SSc are scarce. The rate of preterm deliveries and intrauterine growth restriction (IUGR) seems to be increased, while the risk of miscarriages is controversial. Moreover, no study compared pregnancy outcomes in SSc with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). Read More

View Article and Full-Text PDF

Unusual Initial Presentation Of Primary Antiphospholipid Syndrome As Postpartum Symmetrical Peripheral Gangrene.

J Ayub Med Coll Abbottabad 2022 Jan-Mar;34(1):200-202

Dr Ruth Pfau Civil Hospital Karachi, Pakistan.

Background: Antiphospholipid syndrome (APS) is an acquired prothrombic state with recurring thromboembolic and obstetric complications in the presence of antiphospholipid antibodies. Isolated skin manifestation especially symmetrical peripheral gangrene (SPG) in postpartum phase is reported rarely. To highlight this unusual presentation of APS with SPG we present a case of young female who developed SPG on her third postpartum day. Read More

View Article and Full-Text PDF

Application of thromboelastography in diagnosing normal pregnancies and pregnancies with complications.

J Clin Lab Anal 2022 Jun 24;36(6):e24446. Epub 2022 Apr 24.

Department of Clinical Blood Transfusion, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic Univercity, Edong Healthcare Medical Group, Huangshi, China.

Background: This observational study aimed to compare the potential application of thromboelastography (TEG) in diagnosing women with normal pregnancy (NP) and women with threatened abortion (TA), missed abortion (MA), embryo arrest (EA), fetal death (FD), history of abnormal pregnancy (HAP), and antiphospholipid antibody syndrome (AA).

Methods: According to the relevant clinical criteria, patients were divided into groups, and their blood samples were subjected to TEG. Next, the parameters R, K, α-angle, MA, LY-30, G, and coagulation index (CI) were analyzed. Read More

View Article and Full-Text PDF

Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

J Clin Med 2022 Apr 13;11(8). Epub 2022 Apr 13.

Department of Diagnostic Sciences, Ghent University, 9000 Gent, Belgium.

Diagnosis of antiphospholipid syndrome (APS) requires the presence of a clinical criterion (thrombosis and/or pregnancy morbidity), combined with persistently circulating antiphospholipid antibodies (aPL). Currently, laboratory criteria aPL consist of lupus anticoagulant (LAC), anticardiolipin antibodies (aCL) IgG/IgM, and anti-β2 glycoprotein I antibodies (aβ2GPI) IgG/IgM. Diagnosis and risk stratification of APS are complex and efforts to standardize and optimize laboratory tests have been ongoing since the initial description of the syndrome. Read More

View Article and Full-Text PDF

Antiphospholipid antibodies in women with recurrent embryo implantation failure: A systematic review and meta-analysis.

Autoimmun Rev 2022 Jun 20;21(6):103101. Epub 2022 Apr 20.

Systemic Autoimmune Research Unit, Vall d'Hebron Institut de Recerca, Barcelona, Spain; Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address:

Objective: Antiphospholipid antibodies (aPL) are related to poor pregnancy outcomes, but their effect on embryo implantation is unclear. We aimed to assess the prevalence of different aPL in women with recurrent implantation failure (RIF).

Methods: We searched studies in PubMed (MEDLINE), Scopus and Cochrane Library. Read More

View Article and Full-Text PDF

Upregulated serum granulysin levels in women with antiphospholipid antibody-associated recurrent miscarriage are downregulated by heparin treatment.

Reprod Med Biol 2022 Jan-Dec;21(1):e12460. Epub 2022 Apr 17.

Department of Obstetrics and Gynecology Nippon Medical School Tokyo Japan.

Purpose: Granulysin is a cytotoxic protein that simultaneously activates innate and cellular immunity. The authors aimed to evaluate whether granulysin is associated with the antiphospholipid antibody syndrome and whether heparin changes the granulysin levels.

Methods: A cohort study was performed with women with antiphospholipid antibody-positive recurrent pregnancy loss (RPL). Read More

View Article and Full-Text PDF

Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean.

J Assoc Physicians India 2022 Apr;70(4):11-12

Armed Forces Medical College, Pune, Maharashtra; 2Command Hospital (Southern Command), Pune, Maharashtra.

Antiphospholipid anti body syndrome is an autoimmune disorder characterized by arterial or venous thrombosis and/or pregnancy morbidity with foetal deaths or abortions in the presence of antiphospholipid antibodies. Catastrophic antiphospholipid antibody syndrome (CAPS) is an accelerated form of disease with rapid involvement of multiple organ systems often posing a diagnostic challenge. There is a paucity of literature on the presentations of CAPS owing to the orphan nature of the disease. Read More

View Article and Full-Text PDF

Combined detection of anticardiolipin and anti-β2-glycoprotein 1 antibodies may predict pregnancy outcome.

Am J Transl Res 2022 15;14(3):1750-1756. Epub 2022 Mar 15.

Obstertrics Department, Shijiazhuang Gynecological & Obstetrical Hospital Shijiazhuang 050000, Hebei, China.

Antiphospholipid syndrome (APS) is a typical non-inflammatory autoimmune disease that is common in young women. It is characterized by the presence of the anti-cardiolipin antibody (ACA) and anti-β2 glycoprotein 1 (anti-β2-GP1) antibody and is associated with a high risk of arteriovenous thrombosis. We measured the expression of ACA and anti-β2-GP1 antibodies in the serum of pregnant women early in their pregnancy, and analyzed the pregnancy outcome of the primigravidas who were positive for both the antibodies, so as to evaluate the efficacy of the combined determination in predicting pregnancy outcome. Read More

View Article and Full-Text PDF

Treatment with low-dose prednisone in refractory obstetric antiphospholipid syndrome: A retrospective cohort study and meta-analysis.

Lupus 2022 Jun 11;31(7):808-819. Epub 2022 Apr 11.

Rheumatology Department, 16516Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Background: Glucocorticoids have been suggested as a potential therapy in refractory obstetric antiphospholipid syndrome (oAPS). Our aims were to describe a cohort of patients with oAPS treated with low-dose glucocorticoids and to perform a systematic review and meta-analysis evaluating the effects of additional glucocorticoids on the pregnancy outcomes in oAPS patients.

Methods: Retrospective study that included 11 women diagnosed with primary antiphospholipid syndrome. Read More

View Article and Full-Text PDF

Pregnancy and Management in Women with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Obstetric Antiphospholipid Syndrome.

Rheum Dis Clin North Am 2022 05;48(2):523-535

UT Southwestern Medical Center, 2001 Inwood Road, Dallas, TX 75390, USA. Electronic address:

Management of women with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and obstetric antiphospholipid syndrome (APS) during pregnancy presents unique clinical challenges. Women with both RA and SLE can have disease flares during pregnancy, leading to pregnancy complications, such as preeclampsia, small-for-gestational-age infants, and preterm delivery. Disease should be under control prior to conception. Read More

View Article and Full-Text PDF

Refractory antiphospholipid antibody syndrome-induced thrombocytopaenia successfully treated with belimumab.

Lupus 2022 Apr;31(5):624-627

Department of Rheumatology, 92190Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

Antiphospholipid antibody syndrome (APS) is an autoimmune disease with clinical symptoms such as recurrent arterial/venous thrombosis, pregnancy morbidities and thrombocytopaenia. Antiphospholipid antibodies are suggested to be involved in the pathological condition of APS. Therefore, belimumab (BLM), which reduces autoantibody production from B cells, is expected to be effective in the treatment of APS. Read More

View Article and Full-Text PDF

Care and Treatment for an Antiphospholipid Syndrome-Related Lower Limb Skin Ulcer Unhealed for 7 Years: A Case Report.

Int J Low Extrem Wounds 2022 Mar 31:15347346221090079. Epub 2022 Mar 31.

Wound Care Center, 66506Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.

Antiphospholipid syndrome (APS) is a group of rare autoimmune diseases caused by antiphospholipid antibodies that is mainly associated with arterial or venous thrombosis and/or complications during pregnancy. Skin lesions occur in approximately 30% of APS patients as initial manifestations. However, previous studies have primarily focused on the treatment of APS rather than the management of skin lesions. Read More

View Article and Full-Text PDF

Rheumatic Diseases in Reproductive Age-the Possibilities and the Risks.

Reprod Sci 2022 Mar 31. Epub 2022 Mar 31.

Department of Rheumatology, Rehabilitation and Internal Diseases, Poznan University of Medical Sciences, 28 Czerwca Street 135/147, 60-545, Poznań, Poland.

The most common systemic connective tissue diseases (CTD), such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis (SSc), and Sjögren's syndrome (SjS), affect many women of reproductive age. These diseases may strongly impact the course of pregnancy and increase the risk factors of incompatibility. A literature search was done on MEDLINE, PubMed, and Google Scholar in 2011-2021. Read More

View Article and Full-Text PDF